Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.36 |
| ▸ | FYN | P06241 | 2/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | FEN1 | P39748 | 5/20 | 0.34 |
| ▸ | IGF1R | P08069 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13746535 | 0.93 | CAMKK2 (0.41) | CAMKK2FYNGRM5FEN1ALOX5AP | |
| SCHEMBL13745780 | 0.93 | CAMKK2 (0.41) | CAMKK2FYNGRM5FEN1IGF1R | |
| SCHEMBL13745666 | 0.90 | KDR (0.40) | CAMKK2FYNBRD4 | |
| SCHEMBL13746538 | 0.90 | FYN (0.36) | CAMKK2FYNGRM5IGF1RSCN9A | |
| SCHEMBL13745722 | 0.90 | SCN9A (0.35) | CAMKK2FYNGRM5SCN9ABRD4 | |
| SCHEMBL13746316 | 0.89 | CAMKK2 (0.37) | CAMKK2FYNGRM5FEN1ALOX5AP | |
| SCHEMBL13746336 | 0.88 | CAMKK2 (0.47) | CAMKK2GRM5FEN1IGF1RSCN9A | |
| SCHEMBL13746292 | 0.88 | GSK3B (0.34) | FYN | |
| SCHEMBL13746565 | 0.87 | CAMKK2 (0.39) | CAMKK2FYNBRD4 | |
| SCHEMBL13746271 | 0.87 | CAMKK2 (0.37) | CAMKK2FYNFEN1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | CAMKK2 94/4885FYN 259/4885GRM5 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.